

Catalogue No.

AB0125-200

Qty:

600 µg

Anti-HPV11 E6

Source: Goat

General description: Goat polyclonal antibody to HPV11 E6. E6 is one primary oncoprotein of high risk HPV types expressed early in the HPV life cycle. After the host cell is infected viral early promoter is activated and a polycistronic primary RNA containing all six early ORFs is transcribed. This polycistronic RNA then undergoes active RNA splicing to generate multiple isoforms of mRNAs. One of the spliced isoform RNAs, E6, serves as an E7 mRNA to translate E7 protein. HPV genome integrate into host genome by disruption of E2 ORF, preventing E2 repression on E6 and E7. Thus, viral genome integration into host DNA genome increases E6 expression. The E6 protein inactivates the tumour suppressor protein, p53 and promote cellular proliferation and the chance of malignancy.

Alternative names: N/A

Form: Polyclonal antibody supplied as a 200 µl (3 mg/ml) aliquot in PBS, 20% glycerol and 0.05% sodium azide. This antibody is epitope-affinity purified from goat antiserum.

Immunogen: Purified recombinant peptide derived from within residues 65 aa to N-terminal of HPV11 E6 produced in E. coli.

Specificity: Detects HPV11 E6 recombinant fusion protein GFP-E6 expressed in transfected mammalian cells.

Reactivity: Reacts with HPV11 proteins

Sample	WB	IHC (F)	IHC (P)	IF	ELISA
HPV11	+++	ND	ND	ND	ND


+++ excellent, ++ good, + poor, ND not determined

Usage:

WB: 1:500-1:2,000

Storage: For continuous use, store at 2-8 C for one-two days. For extended storage, store in -20 C freezer. Working dilution samples should be discarded if not used within 12 hours.

Special instructions: The antibody solution should be gently mixed before use..



Anti-HPV11 E6 Ab at 1/1,000 dilution; HEK293 transfected cell lysate at 100 µg per lane; rabbit polyclonal to goat IgG (HRP) at 1/10,000 dilution;

For research use only, not for diagnostic use

SICGEN's Proprietary Immunogen Policy

In order to produce high specific antibodies SICGEN has invested a lot of time and effort into selecting immunogen sequences. SICGEN has decided to protect this information by not publishing it on the website. However, these sequences are available on request.